Monte Rosa raises $25M via pre-funded warrant offering at $2.4999 per share

Monte Rosa Therapeutics, Inc.

Gross proceeds ~$25M from sale of pre-funded warrants to purchase 10,000,400 shares.
Offering price $2.4999 per warrant = Oct 25 closing price less $0.0001 exercise price.
Warrants immediately exercisable at $0.0001; 4.99% beneficial ownership cap (up to 19.99% at holder's election).
Net proceeds to advance pipeline: MRT-2359, MRT-6160 (VAV1 MGD), and NEK7 program.
Closing expected on or about Oct 30, 2023, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Monte Rosa Therapeutics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $25.0 million (effective 2023-10-26).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $25.0 million
Effective: 2023-10-26

Exact text from the filing

Monte Rosa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of pre-funded warrants to purchase 10,000,400 shares of the Company’s common stock

View on SEC.gov

Browse all material agreements →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-264162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.